KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Sarepta Therapeutics (SRPT) FCF Margin: 2012-2025

Historic FCF Margin for Sarepta Therapeutics (SRPT) over the last 11 years, with Jun 2025 value amounting to 37.56%.

  • Sarepta Therapeutics' FCF Margin rose 4148.00% to 37.56% in Q2 2025 from the same period last year, while for Jun 2025 it was -24.43%, marking a year-over-year increase of 925.00%. This contributed to the annual value of -18.02% for FY2024, which is 2840.00% up from last year.
  • According to the latest figures from Q2 2025, Sarepta Therapeutics' FCF Margin is 37.56%, which was up 106.71% from -559.90% recorded in Q1 2025.
  • Over the past 5 years, Sarepta Therapeutics' FCF Margin peaked at 37.56% during Q2 2025, and registered a low of -559.90% during Q1 2025.
  • Over the past 3 years, Sarepta Therapeutics' median FCF Margin value was -33.31% (recorded in 2023), while the average stood at -80.96%.
  • Over the last 5 years, Sarepta Therapeutics' FCF Margin had its largest YoY gain of 12,432bps in 2021, and its largest YoY loss of 68,140bps in 2021.
  • Over the past 5 years, Sarepta Therapeutics' FCF Margin (Quarterly) stood at -15.65% in 2021, then plummeted by 2,318bps to -38.83% in 2022, then surged by 2,026bps to -18.57% in 2023, then skyrocketed by 2,677bps to 8.20% in 2024, then skyrocketed by 4,148bps to 37.56% in 2025.
  • Its last three reported values are 37.56% in Q2 2025, -559.90% for Q1 2025, and 8.20% during Q4 2024.